KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

West Pharmaceutical Services (WST) Revenue (2016 - 2025)

Historic Revenue for West Pharmaceutical Services (WST) over the last 17 years, with Q3 2025 value amounting to $804.6 million.

  • West Pharmaceutical Services' Revenue rose 772.53% to $804.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.0 billion, marking a year-over-year increase of 491.93%. This contributed to the annual value of $2.9 billion for FY2024, which is 191.88% down from last year.
  • As of Q3 2025, West Pharmaceutical Services' Revenue stood at $804.6 million, which was up 772.53% from $766.5 million recorded in Q2 2025.
  • Over the past 5 years, West Pharmaceutical Services' Revenue peaked at $804.6 million during Q3 2025, and registered a low of $670.7 million during Q1 2021.
  • For the 5-year period, West Pharmaceutical Services' Revenue averaged around $727.9 million, with its median value being $723.6 million (2021).
  • Its Revenue has fluctuated over the past 5 years, first skyrocketed by 3725.34% in 2021, then plummeted by 685.86% in 2024.
  • Over the past 5 years, West Pharmaceutical Services' Revenue (Quarter) stood at $730.8 million in 2021, then dropped by 3.02% to $708.7 million in 2022, then increased by 3.29% to $732.0 million in 2023, then grew by 2.3% to $748.8 million in 2024, then increased by 7.45% to $804.6 million in 2025.
  • Its Revenue stands at $804.6 million for Q3 2025, versus $766.5 million for Q2 2025 and $698.0 million for Q1 2025.